CVRx, Inc. (NASDAQ:CVRX) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Mike Vallie - IR Kevin Hykes - President and CEO Jared Oasheim - CFO Conference Call Participants Robbie Marcus - JPMorgan Matthew O'Brien - Piper Sandler Margaret Kaczor Andrew - William Blair Frank Takkinen - Lake Street Capital Market Bill Plovanic - Canaccord Genuity Chase Knickerbocker - Craig-Hallum Capital Group Operator Ladies and gentlemen, good afternoon and welcome to the CVRx Second Quarter 20 ...

This quarterly report represents an earnings surprise of -27.45%. A quarter ago, it was expected that this medical device company would post a loss of $0.53 per share when it actually produced a loss of $1.04, delivering a surprise of -96.23%. CVRx, which belongs to the Zacks Medical - Instruments industry, posted revenues of $11.81 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 0.28%. This compares to year-ago revenues of $9.5 million. The company has topped consensus reve ...

Recent Highlights Exhibit 99.1 MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. · U.S. Heart Failure (HF) revenue for the second quarter of 2024 was $10.5 million, an increase of 27% over the prior year quarter Seco ...

MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2024. "We are pleased with our solid second quarter results, driven by another record quarter in our U.S. Heart Failure business. We remain extremely optimistic about the B ...

MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release second quarter 2024 financial and operating results after market close on Monday, July 29th, 2024. The Company will host a conference call to review its results at 4:30pm E ...

MINNEAPOLIS, July 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release second quarter 2024 financial and operating results after market close on Monday, July 29th, 2024. The Company will host a conference call to review its results at 4:30pm E ...

CVRx stock rallied following the company's announcement to appoint Robert John as Chief Revenue Officer effective June 27. CVRx management expects John's presence will help the company to expand the adoption of Barostim therapy. For CVRx, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CVRX going forward to see if this rec ...

John brings over 25 years of sales leadership experience in the medical device industry, with a strong track record of building high-performing sales teams. Most recently, he served as Divisional Vice President and General Manager of Cardiac Rhythm Management EMEA at Abbott, where he led a global business unit spanning over 90 countries. Prior to this role, he was first Senior Vice President, then the Divisional Vice President of the Heart Failure business, responsible for integrating the Thoratec and Cardi ...

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. John brings over 25 years of sales leadership experience ...

CVRx scored a strong price increase driven by the optimism surrounding the company's recent presentation at William Blair 44rd Annual Growth Stock Conference held on Jun 5, 2024. The company drew attention to the massive $2.2 billion U.S. annual net addressable market for Barostim device and plans to drive the therapy to a standard of care. In addition, CVRx reaffirmed its financial outlook for the second quarter and full year 2024, issued during the first quarter earnings call. For CVRx, the consensus EPS ...